FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003234142> ?p ?o ?g. }

• W2003234142 endingPage "30806" @default.
• W2003234142 startingPage "30800" @default.
• W2003234142 abstract "Cardiac and skeletal muscle genes are regulated by the transcriptional enhancer factor (TEF-1) family of transcription factors. In skeletal muscle, TEF-1 factors interact with a skeletal muscle-specific cofactor called Vestigial-like 2 (Vgl-2) that is related to the Drosophila protein Vestigial. Here, we characterize Vgl-4, the only member of the Vestigial-like family expressed in the heart. Unlike other members of the Vgl family that have a single TEF-1 interaction domain called the tondu (TDU) motif, Vgl-4 has two TDU motifs in its carboxyl-terminal domain. Like other Vgl factors, Vgl-4 physically interacts with TEF-1 in an immunoprecipitation assay. Vgl-4 functionally interacts with TEF-1 and also with myocyte enhancer factor 2 in a mammalian two-hybrid assay. Overexpression of Vgl-4 in cardiac myocytes interfered with the basal expression and α1-adrenergic receptor-dependent activation of a TEF-1-dependent skeletal α-actin promoter. In cardiac myocytes cultured in serum and in serum-free medium, a myc-tagged Vgl-4 protein was located in the nucleus and cytoplasm but was exported from the nucleus when cells were treated with α1-adrenergic receptor agonist. A chimeric nuclear-retained Vgl-4 protein inhibited α1-adrenergic receptor-dependent activation. In contrast, deletion of the TDU motifs of Vgl-4 prevented Vgl-4 nuclear localization, relieved Vgl-4 interference of basal activity, and enhanced α1-adrenergic up-regulation of the skeletal α-actin promoter. Nuclear export of Vgl-4 is dependent on the nuclear exportin CRM-1. These results suggest that Vgl-4 modulates the activity of TEF-1 factors and counteracts α1-adrenergic activation of gene expression in cardiac myocytes. Cardiac and skeletal muscle genes are regulated by the transcriptional enhancer factor (TEF-1) family of transcription factors. In skeletal muscle, TEF-1 factors interact with a skeletal muscle-specific cofactor called Vestigial-like 2 (Vgl-2) that is related to the Drosophila protein Vestigial. Here, we characterize Vgl-4, the only member of the Vestigial-like family expressed in the heart. Unlike other members of the Vgl family that have a single TEF-1 interaction domain called the tondu (TDU) motif, Vgl-4 has two TDU motifs in its carboxyl-terminal domain. Like other Vgl factors, Vgl-4 physically interacts with TEF-1 in an immunoprecipitation assay. Vgl-4 functionally interacts with TEF-1 and also with myocyte enhancer factor 2 in a mammalian two-hybrid assay. Overexpression of Vgl-4 in cardiac myocytes interfered with the basal expression and α1-adrenergic receptor-dependent activation of a TEF-1-dependent skeletal α-actin promoter. In cardiac myocytes cultured in serum and in serum-free medium, a myc-tagged Vgl-4 protein was located in the nucleus and cytoplasm but was exported from the nucleus when cells were treated with α1-adrenergic receptor agonist. A chimeric nuclear-retained Vgl-4 protein inhibited α1-adrenergic receptor-dependent activation. In contrast, deletion of the TDU motifs of Vgl-4 prevented Vgl-4 nuclear localization, relieved Vgl-4 interference of basal activity, and enhanced α1-adrenergic up-regulation of the skeletal α-actin promoter. Nuclear export of Vgl-4 is dependent on the nuclear exportin CRM-1. These results suggest that Vgl-4 modulates the activity of TEF-1 factors and counteracts α1-adrenergic activation of gene expression in cardiac myocytes. Differentiation of cardiac and skeletal muscle from pluripotent embryonic stem cells requires the selective activation of a limited number of transcription factors that drive the expression of many genes that confer the tissue-specific phenotype. The transcriptional enhancer factor-1 (TEF-1) 1The abbreviations used are: TEF-1, transcriptional enhancer factor-1; Vgl, Vestigial-like; TDU, tondu; MEF2, myocyte enhancer factor 2.1The abbreviations used are: TEF-1, transcriptional enhancer factor-1; Vgl, Vestigial-like; TDU, tondu; MEF2, myocyte enhancer factor 2. family of transcription factors is required for muscle-specific gene activation. TEF-1 was identified from the characterization of the cardiac troponin T promoter. Cardiac troponin T is expressed in fetal skeletal muscle and in cardiac muscle. Mutation analysis of the cardiac troponin T promoter showed that the MCAT element (originally defined as a muscle-specific cytidine-adenosine-thymidine sequence, 5′-CATTCCT-3′) is required for high levels of promoter activity in cardiac and skeletal muscle cells (1Mar J.H. Ordahl C.P. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 6404-6408Crossref PubMed Scopus (113) Google Scholar, 2Mar J.H. Ordahl C.P. Mol. Cell. Biol. 1990; 10: 4271-4283Crossref PubMed Scopus (148) Google Scholar). Similar MCAT elements have been characterized in a large number of skeletal and cardiac muscle-specific promoters (3Larkin S.B. Farrance I.K.G. Ordahl C.P. Mol. Cell. Biol. 1996; 16: 3742-3755Crossref PubMed Scopus (72) Google Scholar). The transcription factor that binds to this element was identified as the SV40 enhancer-binding factor TEF-1 (4Farrance I.K. Mar J.H. Ordahl C.P. J. Biol. Chem. 1992; 267: 17234-17240Abstract Full Text PDF PubMed Google Scholar). TEF-1 is expressed in many tissues (5Stewart A.F.R. Richard III, C.W. Suzow J. Stephan D. Weremowicz S. Morton C.C. Adra C.N. Genomics. 1996; 37: 68-76Crossref PubMed Scopus (35) Google Scholar), and TEF-1 has also been implicated in placenta-specific enhancer function (6Jiang S.-W. Eberhardt N.L. J. Biol. Chem. 1994; 269: 10384-10392Abstract Full Text PDF PubMed Google Scholar, 7Jacquemin P. Oury C. Belayew A. Martial J.A. DNA Cell Biol. 1994; 13: 1037-1045Crossref PubMed Scopus (15) Google Scholar). Thus, the mechanism whereby TEF-1 confers tissue specificity to an MCAT-bearing promoter has been ascribed to the interaction of TEF-1 with tissue-specific cofactors. For example, both the human placental lactogen promoter (6Jiang S.-W. Eberhardt N.L. J. Biol. Chem. 1994; 269: 10384-10392Abstract Full Text PDF PubMed Google Scholar, 7Jacquemin P. Oury C. Belayew A. Martial J.A. DNA Cell Biol. 1994; 13: 1037-1045Crossref PubMed Scopus (15) Google Scholar) and the β-myosin heavy chain promoter (8Tsika R.W. McCarthy J. Karasseva N. Ou Y. Tsika G.L. Am. J. Physiol. Cell Physiol. 2002; 283: C1761-C1775Crossref PubMed Scopus (12) Google Scholar, 9Huey K.A. Haddad F. Qin A.X. Baldwin K.M. Am. J. Physiol. Cell Physiol. 2003; 284: C738-C748Crossref PubMed Scopus (25) Google Scholar) contain MCAT elements and are TEF-1-dependent for their specific expression in placenta and muscle, respectively. Thus, placenta- and muscle-specific TEF-1 cofactors must confer tissue-specific activity of TEF-1-dependent promoters. Studies in Drosophila have identified an important role for a cofactor of the TEF-1 homologue scalloped during wing and flight muscle differentiation (10Bate M. Rushton E. C. R. Acad. Sci. (Paris). 1993; 316: 1047-1061PubMed Google Scholar, 11Sudarsan V. Anant S. Guptan P. VijayRaghavan K. Skaer H. Dev. Cell. 2001; 1: 829-839Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar). This cofactor, called Vestigial, is critical for the development and patterning of the wing: loss of Vestigial results in a failure of wing development, and ectopic expression of Vestigial in tissues of the eyes, legs, and antennae leads to the development of ectopic wing tissue (12Kim J. Sebring A. Esch J.J. Kraus M.E. Vorwerk K. Magee J. Carroll S.B. Nature. 1996; 382: 133-138Crossref PubMed Scopus (395) Google Scholar, 13Halder G. Polaczyk P. Kraus M.E. Hudson A. Kim J. Laughon A. Carroll S. Genes Dev. 1998; 12: 3900-3909Crossref PubMed Scopus (185) Google Scholar). Binding of Vestigial switches the DNA target selectivity of the Scalloped protein (14Halder G. Carroll S.B. Development (Camb.). 2001; 128: 3295-3305PubMed Google Scholar) and activates many wing and flight muscle-specific genes. These studies suggest that Vestigial acts as a selector protein controlling tissue-specific gene activation during organogenesis. We and others have identified mammalian homologues of Vestigial (14Halder G. Carroll S.B. Development (Camb.). 2001; 128: 3295-3305PubMed Google Scholar, 15Vaudin P. Delanoue R. Davidson I. Silber J. Zider A. Development (Camb.). 1999; 126: 4807-4816Crossref PubMed Google Scholar, 16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar, 17Mielcarek M. Günther S. Kruger M. Braun T. Mech. Dev. 2002; 119: S269-S274Crossref PubMed Scopus (25) Google Scholar). The first human homologue of Vestigial was named Tondu (the French word for “shaved”), perhaps because it could partially rescue the wing phenotype caused by a null mutation in Drosophila Vestigial (15Vaudin P. Delanoue R. Davidson I. Silber J. Zider A. Development (Camb.). 1999; 126: 4807-4816Crossref PubMed Google Scholar). In a Northern blot of fetal human tissues, Tondu was found to be expressed in the kidney and lung, but not in the brain or the heart (15Vaudin P. Delanoue R. Davidson I. Silber J. Zider A. Development (Camb.). 1999; 126: 4807-4816Crossref PubMed Google Scholar). Tondu was shown to physically and functionally interact with TEF-1 through a conserved sequence called the tondu (TDU) motif. We also identified this factor but named it Vestigial-like (Vgl)-1. Northern blot analysis of adult human tissues showed that it is expressed almost exclusively in the placenta (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). We identified two other genes that bear a TDU motif and called them Vgl-2 and Vgl-3, although these proteins have little homology outside the TDU motif. Vgl-3 was also found to be placenta-specific. Thus, Vgl-1 and Vgl-3 likely contribute to the placenta-specific activity of TEF-1. In the adult, Vgl-2 was detected only in skeletal muscle. Vgl-2 is expressed in the myogenic cell line C2C12, and Vgl-2 mRNA levels increase during muscle differentiation. Using a mammalian two-hybrid assay, we found that Vgl-2 also interacts with TEF-1 factors through its TDU motif. In addition, we found that Vgl-2 uses the TDU motif to interact with the transcription factor myocyte enhancer factor (MEF) 2 (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). Interestingly, Vgl-2 activated a TEF-1-dependent promoter and a MEF2-dependent promoter in myotubes, but not in myoblasts. By in situ hybridization in fetal mice, Vgl-2 mRNA appeared in early muscle precursors together with the myogenic differentiation factor myogenin (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). Co-expression of Vgl-2 with MyoD, another myogenic differentiation factor, enhanced MyoD-induced muscle differentiation of 10T½ cells with a 7-fold increase in myosin heavy chain expression (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). From these functional properties, because Vgl-2 is skeletal muscle-specific and is expressed at the onset of skeletal muscle differentiation in the somitic myotome, Vgl-2 likely accounts for the skeletal muscle-specific function ascribed to TEF-1. However, a similar tissue-restricted member of the Vestigial-like family of cofactors had not been identified in the heart. Differentiation of cardiac muscle progenitor cells involves the selective activation of the GATA4 and Nkx2.5 transcription factors in pluripotent mesoderm (18Komuro I. Izumo S. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 8145-8149Crossref PubMed Scopus (462) Google Scholar, 19Kuo C.T. Morrisey E.E. Anandappa R. Sigrist K. Lu M.M. Parmacek M.S. Soudais C. Leiden J.M. Genes Dev. 1997; 11: 1048-1060Crossref PubMed Scopus (868) Google Scholar, 20Sepulveda J.L. Belaguli N. Nigam V. Chen C.Y. Nemer M. Schwartz R.J. Mol. Cell. Biol. 1998; 18: 3405-3415Crossref PubMed Scopus (277) Google Scholar). However, because mutation of TEF-1 binding sequences in the promoters of cardiac-specific genes causes a loss of tissue specificity (2Mar J.H. Ordahl C.P. Mol. Cell. Biol. 1990; 10: 4271-4283Crossref PubMed Scopus (148) Google Scholar), and because ablation of TEF-1 expression causes abnormal cardiac development and an embryonic lethal phenotype (21Chen Z. Friedrich G.A. Soriano P. Genes Dev. 1994; 8: 2293-2301Crossref PubMed Scopus (262) Google Scholar), these studies support a role for TEF-1 factors in cardiac development. In the adult, cardiac myocytes respond to growth-promoting stimuli by undergoing hypertrophy, rather than cell division. Although cardiac myocytes are considered to be terminally differentiated, hypertrophic signals such as the α1-adrenergic receptor agonist phenylephrine induce the expression of a number of genes characteristically expressed in the fetal heart (22Kariya K. Farrance I.K. Simpson P.C. J. Biol. Chem. 1993; 268: 26658-26662Abstract Full Text PDF PubMed Google Scholar, 23Karns L.R. Kariya K. Simpson P.C. J. Biol. Chem. 1995; 270: 410-417Abstract Full Text Full Text PDF PubMed Scopus (162) Google Scholar) and also partially reactivate specific components of the cell cycle machinery, including members of the E2F family of transcription factors (24Vara D. Bicknell K.A. Coxon C.H. Brooks G. J. Biol. Chem. 2003; 278: 21388-21394Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar) and cyclin D (25Busk P.K. Bartkova J. Strom C.C. Wulf-Andersen L. Hinrichsen R. Christoffersen T.E. Latella L. Bartek J. Haunso S. Sheikh S.P. Cardiovasc. Res. 2002; 56: 64-75Crossref PubMed Scopus (64) Google Scholar). Thus, myocytes transit through the G1-S phase of the cell cycle but appear unable to reenter a proliferative state. TEF-1 factors have been implicated in the activation of fetal genes in response to hypertrophic signals (22Kariya K. Farrance I.K. Simpson P.C. J. Biol. Chem. 1993; 268: 26658-26662Abstract Full Text PDF PubMed Google Scholar, 23Karns L.R. Kariya K. Simpson P.C. J. Biol. Chem. 1995; 270: 410-417Abstract Full Text Full Text PDF PubMed Scopus (162) Google Scholar, 26McLean B.G. Lee K.S. Simpson P.C. Farrance I.K. J. Mol. Cell. Cardiol. 2003; 35: 461-471Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar, 27Stewart A.F.R. Suzow J. Kubota T. Ueyama T. Chen H.H. Circ. Res. 1998; 83: 43-49Crossref PubMed Scopus (65) Google Scholar, 28Ueyama T. Zhu C. Valenzuela Y.M. Suzow J.G. Stewart A.F.R. J. Biol. Chem. 2000; 275: 17476-17480Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 29Maeda T. Mazzulli J.R. Farrance I.K. Stewart A.F.R. J. Biol. Chem. 2002; 277: 24346-24352Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar). If cardiac myocytes could be induced to dedifferentiate and reenter the cell cycle, this would represent an exploitable strategy to repair injured myocardium after myocardial infarction. Alternatively, expansion and modification of adult stem cells could also provide a means of regenerating injured tissue (30Beltrami A.P. Barlucchi L. Torella D. Baker M. Limana F. Chimenti S. Kasahara H. Rota M. Musso E. Urbanek K. Leri A. Kajstura J. Nadal-Ginard B. Anversa P. Cell. 2003; 114: 763-776Abstract Full Text Full Text PDF PubMed Scopus (2984) Google Scholar). In the present study, we characterized Vgl-4, a novel member of the Vgl family of TEF-1 cofactors. Vgl-4 was initially identified as a transcript expressed in an adult human myeloid leukemia bone marrow-derived stem cell line (31Nagase T. Seki N. Tanaka A. Ishikawa K. Nomura N. DNA Res. 1995; 2 (199-210): 167-174Crossref PubMed Scopus (137) Google Scholar). Vgl-4 is the only Vgl member expressed in the heart. Unlike other members of the Vestigial family, Vgl-4 has two TDU motifs, suggesting that Vgl-4 might form a bridge between TEF-1 and MEF2 transcription factors. Mammalian two-hybrid analysis showed that Vgl-4 interacts with MEF2 and TEF-1. Overexpression of Vgl-4 in transient transfection assays in cardiac myocytes squelched a TEF-1-depedent skeletal α-actin promoter and interfered with its α1-adrenergic induction. Vgl-4 becomes localized to the cytoplasm with α1-adrenergic stimulation, suggesting that it is part of a dedifferentiated phenotype. Whereas the functional role of Vgl-4 in cardiac development remains to be elucidated, its interaction with and modulation of known cardiac and skeletal muscle transcription factors reveal a novel component of cardiac muscle differentiation. Expression Plasmids and Constructs—The full-length human (BQ932927) and mouse (BC048841) Vgl-4 cDNAs were obtained from Open Biosystems (Huntsville, AL). The human Vgl-4 cDNA was released from the pOTB7 plasmid using EcoRI and XhoI, labeled by random hexamer oligonucleotide priming, and used for Northern blot analysis of gene expression with a multi-tissue Northern blot (Clontech). The EcoRI/XhoI fragment was ligated into the human cytomegalovirus enhancer-driven expression vector pXJ40. To generate a myc-tagged Vgl-4 protein, the mouse Vgl-4 cDNA cloned in the pCMV-SPORT6 expression vector was released by a HindIII digest, filled-in with Klenow, and a XhoI digest. The fragment encoding amino acids 29–287 was ligated in-frame to a SmaI/XhoI-linearized pBluescript-myc tag vector to obtain the pBSmycVgl-4 vector. From the pBSmycVgl-4 vector, an NcoI/XhoI fragment encoding myc-tagged mouse Vgl-4 was ligated into the NcoI/XhoI-linearized pXJ40 expression vector to obtain the pXJmycVgl-4 vector. A chimeric construct bearing the amino-terminal domain of TEF-1 carrying the DNA-binding domain and nuclear localization signal fused to the mycVgl-4 cDNA sequence was obtained by ligating an EcoRI/filled-in BamHI fragment of TEF-1 in-frame to a filled-in NcoI/XhoI fragment of mycVgl-4 into an EcoRI/XhoI linearized pXJ40 vector. A mycVgl-4 expression construct lacking the TDU motifs was obtained by releasing and filling-in a SapI/XhoI digest of pXJmycVgl-4, thereby deleting the carboxyl terminus from amino acid 192. For the mammalian two-hybrid analysis, the pG5-luciferase reporter plasmid (Promega) was used. The pMTEF-1 vector (containing the coding sequence for the yeast GAL4 DNA-binding domain fused to the human TEF-1 cDNA encoding amino acids 168–426) and the pMMEF2 vector (containing GAL4 DNA-binding sequence fused to the full-length MEF2C sequence) have been described previously (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). The pVP16 vector (encoding the activation domain of the herpes simplex virus VP16 protein) was linearized with MluI and PstI. A BssHII/PstI fragment of the human Vgl-4 cDNA encoding amino acids 113–296 of the carboxyl terminus of Vgl-4 was ligated in-frame to the MluI/PstI-linearized pVP16 vector to generate the pVPVgl-4 vector. The pVPVgl-4ΔTDU vector, which lacked both TDU1 and TDU2, was obtained by filling in an EcoNI site and ligating to an Eco47III site in Vgl-4, thereby deleting the sequence coding for amino acids 207–273. The pVPVgl-4TDU1 vector was obtained by cloning a NaeI fragment coding for amino acids 153–232 of human Vgl-4 into the pVP vector at the filled-in BamHI site. The pVPVgl-4TDU2 vector was obtained by cloning a 3′ NaeI/HindIII fragment coding for amino acids 233–296 into the pVP vector between the filled-in EcoRI and the HindIII sites. All constructs were sequenced at the University of Pittsburgh core facility. In Vitro Translation and Co-immunoprecipitation—The pXJTEF-1 and pXJmycVgl-4 plasmids were transcribed with T7 polymerase and translated in vitro (Promega) to produce unlabeled full-length human TEF-1 and myc-tagged mouse Vgl-4 proteins. Incorporation of [35S]methionine was also used to produce radiolabeled proteins for immunoprecipitation. Reticulocyte lysates were precleared with protein A-Sepharose in lysis buffer (50 mm Tris, pH 7.4, 150 mm NaCl, and 1% Igepal CA-630 supplemented with protease inhibitors). Unlabeled mycVgl-4 was incubated with radiolabeled TEF-1 and immunoprecipitated using a rabbit anti-myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and unlabeled TEF-1 protein was incubated with radiolabeled mycVgl-4 and immunoprecipitated with a mouse monoclonal anti-TEF-1 antibody (BD Transduction Laboratories, San Diego, CA). Proteins were size-fractionated by SDS-PAGE, the gel was dried down, and radiolabeled proteins were visualized on a phosphor storage screen (Amersham Biosciences). Tissue Culture and Transfection—Neonatal rat cardiac myocytes were isolated as described previously (32Simpson P. J. Clin. Investig. 1983; 72: 732-738Crossref PubMed Scopus (550) Google Scholar), except that Worthington type II collagenase (5 mg/ml in Hank's balanced salt solution, 0.8 mm MgSO4, 20 mm Hepes, pH 7.4, and 1% glucose) was substituted for trypsin. Myocytes were cultured at low density (5 × 106 viable cells/well of a 6-well dish) in Hank's minimal essential medium supplemented with 5% fetal bovine serum and bromodeoxyuridine (100 μm) to prevent non-myocyte proliferation. Twenty-four h after plating, the medium was replaced with fresh medium containing 30 mm Hepes, pH 7.4, and transfected using the calcium phosphate precipitation method for 2 h with serum-containing medium, as described previously (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). After transfection, cells were rinsed several times, maintained in serum-free medium for 2 days, and harvested for the luciferase assay, as described previously (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). Activities (mean ± S.E.) of the skeletal α-actin promoter were normalized to basal activity when co-transfected with empty pXJ40 expression vector and set at 1-fold. By independent sample t test, mean fold activities of the skeletal α-actin promoter response to phenylephrine in the presence of overexpressed TEF-1 transcription factors and the Vgl-4 cofactor were considered different from the response in the presence of empty expression vector at the p < 0.05 significance level. CV-1 fibroblasts maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in 6-well plates were transfected with 0.7 μg of the pG5-luciferase reporter (Promega) and 0.1 μg each of the pM and pVP expression vectors (Clontech) using LipofectAMINE™ reagent (Invitrogen). For immunofluorescence detection of mycVgl-4, CV-1 cells and cardiac myocytes were plated and transfected on two-chamber collagen-coated glass slides. Cells were permeabilized and fixed in 0.1% Triton X-100 and 4% paraformaldehyde in phosphate-buffered saline. The myc-tagged protein was detected using a c-myc (A-14) rabbit antibody (Santa Cruz Biotechnology) and visualized with Cy2-conjugated donkey anti-rabbit antibody (Jackson ImmunoResearch, West Grove, PA). Myosin heavy chain was revealed using MF20 mouse monoclonal antibody (Developmental Studies Hybridoma bank, University of Iowa) visualized with Cy3-conjugated donkey anti-mouse antibody (Jackson ImmunoResearch, West Grove, PA). Nuclei were visualized with 4′,6-diamidino-2-phenylindole (1 mg/ml; Roche Applied Science). Vgl-4 was identified in the SMART (Simple Modular Architecture Research Tool; smart.ox.ac.uk/) data base as a protein containing two tandem TDU motifs (Fig. 1). A putative nuclear export signal and binding site for interaction with the nuclear exportin CRM-1 having the consensus sequence LX1–3 LX2–4LXL (33Fabbro M. Henderson B.R. Exp. Cell Res. 2003; 282: 59-69Crossref PubMed Scopus (196) Google Scholar) was also identified in Vgl-4. Originally described as a putative protein encoded by a cDNA (KIAA0121) isolated from a human bone marrow stem cell-derived cell line (31Nagase T. Seki N. Tanaka A. Ishikawa K. Nomura N. DNA Res. 1995; 2 (199-210): 167-174Crossref PubMed Scopus (137) Google Scholar), Vgl-4 is unique among the Vgl family of cofactors in that its expression is not tissue-restricted in the adult human (Fig. 2). Whereas Vgl-1 and Vgl-3 are largely placenta-enriched and Vgl-2 is skeletal muscle-specific (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar), Vgl-4 is expressed in the heart, kidney, and brain as well as in other tissues at lower levels.Fig. 2Northern blot analysis of Vgl-4 expression in human tissues. A human multi-tissue Northern blot with 1 μg mRNA/lane was probed for Vgl-4 expression. Vgl-4 expression was highest in the heart, kidney, and brain. Position of size markers is indicated.View Large Image Figure ViewerDownload (PPT) Because the two TDU motifs diverge from those previously described for other members of the Vgl family (Fig. 1B), we tested whether Vgl-4 could also interact with TEF-1 (Fig. 3). Functional interaction between TEF-1 and Vgl-4 was observed by two-hybrid analysis in transiently transfected CV-1 cells (Fig. 3A; p < 0.001), and physical interaction was confirmed by co-immunoprecipitation (Fig. 3B). In addition, like Vgl-1 and Vgl-2 (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar), Vgl-4 interacts with MEF2 (Fig. 3A; p < 0.001). Interestingly, when half the pMTEF-1 and half the pMMEF2 vectors were both expressed with pVP-Vgl-4, a stronger interaction was observed than with pMTEF-1 and pMMEF2 vector alone (p < 0.0001). On the other hand, Vgl-1 contains a single TDU motif, and when pVP-Vgl-1 was similarly co-expressed with pMTEF-1 and pMMEF2, enhanced interaction was not seen (data not shown), suggesting that the presence of tandem TDU motifs in Vgl-4 allows TEF-1 and MEF2 to bind to Vgl-4 at the same time. In-frame deletion of both TDU motifs in Vgl-4 prevents Vgl-4 interaction with TEF-1 and MEF2 (Fig. 4). Although TDU1 preferentially interacted with TEF-1 (Fig. 4A), and TDU2 preferentially interacted with MEF2 (Fig. 4B), neither TDU motif alone was sufficient to restore full interaction with TEF-1 or MEF2.Fig. 4The TDU motifs are required for Vgl-4 interaction with TEF-1 and MEF2. Using the mammalian two-hybrid assay in CV-1 cells, an in-frame deletion of the TDU motifs in human Vgl-4 prevents its interaction with TEF-1 (A) and MEF2 (B). The TDU1 motif weakly interacted with TEF-1 (A), but not with MEF2 (B). In contrast, the TDU2 motif did not interact with TEF-1 (A) but interacted weakly with MEF2 (B). All values, n = 6.View Large Image Figure ViewerDownload (PPT) To directly test whether the interaction between Vgl-4 and TEF-1 modulates the transcriptional activity of TEF-1, we used the mammalian two-hybrid assay in cardiac myocytes (Fig. 5). Vgl-4 alone does not affect the expression of the GAL4-dependent promoter (compare pM/pVP with pM/pVPVgl-4). When fused to the GAL4 DNA-binding domain, TEF-1 is a moderately strong transcriptional activator of a heterologous GAL4-dependent promoter, pG5-luciferase, in cardiac myocytes (Fig. 5, pMTEF-1), but not in CV-1 cells (Fig. 3), as reported previously (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). α1-Adrenergic signaling increases reporter gene expression in the presence of GAL4/TEF-1 (pMTEF-1), but not in the presence of the GAL4 DNA-binding domain alone (pM). Thus, α1-adrenergic signaling increases TEF-1 transcriptional activity. Interaction between Vgl-4 and TEF-1 was also observed in cardiac myocytes (compare pMTEF-1/pVP with pMTEF-1/pVPVgl-4; p < 0.01), as it was in CV-1 cells (Fig. 3). However, in the presence of Vgl-4, the α1-adrenergic signaling-mediated potentiation of TEF-1 function was prevented (Fig. 5, compare pMTEF-1/pVPVgl-4 with pMTEF-1/pVPVgl-4/PE; p < 0.02). To determine how Vgl-4 modulates the α1-adrenergic signaling-mediated potentiation of TEF-1 function, a myc-tagged Vgl-4 protein was expressed in cardiac myocytes by transient transfection. In cardiac myocytes cultured in 5% fetal bovine serum or in serum-free medium, mycVgl-4 was localized predominantly in the nucleus (Fig. 6, A and C). However, 24 h after phenylephrine stimulation, mycVgl-4 was predominantly exported to the cytoplasm, and little signal remained in the nuclei of cultured cardiac myocytes (Fig. 6E). To determine how Vgl-4 regulates gene expression in cardiac myocytes, the effect of Vgl-4 overexpression was tested on a TEF-1-dependent α-skeletal actin promoter (Fig. 7). Vgl-4 overexpression lowered the basal activity of the α-skeletal actin promoter (p < 0.01), suggesting that Vgl-4 is a negative modulator of TEF-1. The α-skeletal actin gene is up-regulated by the α1-adrenergic receptor-selective agonist phenylephrine up to 6-fold (Fig. 7). The response of the skeletal α-actin promoter to phenylephrine was blunted by TEF-1 overexpression (p < 0.01), by Vgl-4 overexpression (p < 0.02), or when Vgl-4 was co-expressed with TEF-1 (p < 0.0001). Taking into account that Vgl-4 is largely exported from the nucleus of phenylephrine-treated cardiac myocytes (Fig. 6), the ability of Vgl-4 overexpression to abrogate the α1-adrenergic activation of the skeletal α-actin promoter might be enhanced if it were made to remain in the nucleus. To test whether a strong nuclear localization signal could override phenylephrine-mediated nuclear export of Vgl-4, a chimeric protein was generated using the nuclear localization signal of TEF-1 fused to mycVgl-4. This chimeric protein, TEF(N)-mycVgl-4, is not exported from the nucleus of cardiac myocytes treated with phenylephrine (Fig. 8, C and D). When tested on the skeletal α-actin promoter, the chimeric protein that is resistant to nuclear export nearly ablated the α1-adrenergic response (Fig. 7). On the other hand, deleting the carboxyl-terminal domain of Vgl-4 containing both TDU motifs caused cytoplasmic retention of Vgl-4 (Fig. 8, E and F) and markedly increased the α1-adrenergic up-regulation of the skeletal α-actin promoter (Fig. 7). To determine whether the mechanism that regulates nuclear shuttling of Vgl-4 in cardiac myocytes requires the nuclear exportin CRM-1, as suggested by the presence of a putative nuclear export signal (Fig. 1), cardiac myocytes treated with phenylephrine were also treated with the CRM-1 inhibitor leptomycin B (Fig. 9). Leptomycin B blocked nuclear export of Vgl-4 in phenylephrine-treated cardiac myocytes. In the present study, we have identified Vgl-4 as a novel member of the Vgl family of transcription cofactors. Vgl-4 is expressed in several tissues, with the highest expression seen in the heart, followed by the kidney and brain (Fig. 2). This is the first member of the Vestigial family to be identified in the heart. Like other members of this family, united by the TDU motif, Vgl-4 interacts with TEF-1 and MEF2 in cultured cells. Thus, Vgl-4 joins a growing list of transcription factors and cofactors known to interact with TEF-1. Vgl-4 carries two TDU motifs required for the interaction with TEF-1 and MEF2, as supported by the two-hybrid analysis (Figs. 3 and 4). Vgl-4 may serve an important function bridging TEF-1 and MEF2 in cardiac muscle. The presence of two tandem TDU motifs in Vgl-4 is unique among vertebrate Vgl family members but is also seen in hypothetical proteins of Drosophila melanogaster (NP_648658) and Caenorhabditis elegans (AAK82912) that are distinct from Vestigial. However, the function of these other invertebrate Vestigial-like factors is not known. Interestingly, the first and second TDU motifs of the Drosophila protein are spaced farther apart and are different from each other (Fig. 1A), yet they show remarkable similarity to the equivalent TDU motifs in Vgl-4, suggesting that these motifs are conserved and may be functionally distinct. In support of this hypothesis, TDU1 and TDU2 showed selective interaction with TEF-1 and MEF2, respectively (Fig. 4). The existence of another protein in Drosophila bearing tandem TDU motifs points to a very ancient origin of the Vgl family. TEF-1 forms a multi-protein complex with other transcription factors including the histone-modifying enzyme poly(ADP-ribose) polymerase 1 (34Butler A.J. Ordahl C.P. Mol. Cell. Biol. 1999; 19: 296-306Crossref PubMed Scopus (170) Google Scholar), the serum response factor (35Gupta M. Kogut P. Davis F.J. Belaguli N.S. Schwartz R.J. Gupta M.P. J. Biol. Chem. 2001; 276: 10413-10422Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar), and MEF2 (36Maeda T. Gupta M.P. Stewart A.F.R. Biochem. Biophys. Res. Commun. 2002; 294: 791-797Crossref PubMed Scopus (59) Google Scholar). Among transcriptional co-activators, the p160 proteins (37Belandia B. Parker M.G. J. Biol. Chem. 2000; 275: 30801-30805Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar), the Src/Yes-associated protein Yap65 (38Vassilev A. Kaneko K.J. Shu H. Zhao Y. DePamphilis M.L. Genes Dev. 2001; 15: 1229-1241Crossref PubMed Scopus (537) Google Scholar), and Vgl-2 (16Maeda T. Chapman D.L. Stewart A.F.R. J. Biol. Chem. 2002; 277: 48889-48898Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar) are able to augment transcription from an MCAT-dependent promoter. Unlike Vgl-2 in skeletal muscle, Vgl-4 appears to be a negative regulator of TEF-1-dependent gene expression in cardiac myocytes when tested on the TEF-1-dependent skeletal α-actin promoter (Fig. 7) and on the β-myosin heavy chain promoter (data not shown). Similarly, Vgl-4 interfered with the activity of a MEF2-dependent myosin light chain promoter in cardiac myocytes (data not shown). Vgl-4 interference with TEF-1-dependent promoter activity under basal conditions suggests either that Vgl-4 itself is a negative cofactor or that Vgl-4 recruits a negative factor to TEF-1. If Vgl-4 is a negative cofactor, blocking its interaction with TEF-1 should have restored baseline skeletal α-actin promoter activity. If Vgl-4 recruits a negative factor to TEF-1, then blocking Vgl-4 interaction with TEF-1 would allow overexpressed mutant Vgl-4 to compete for binding to the negative factor with endogenous Vgl-4, relieve the inhibition of the TEF-1 complex, and further increase the baseline activity of the skeletal α-actin promoter. Consistent with the latter hypothesis, a carboxyl-terminal-truncated Vgl-4 lacking the TDU motifs augmented the basal activity of the skeletal α-actin promoter (Fig. 7). The skeletal α-actin promoter is activated by α1-adrenergic stimulation, and this response requires TEF-1 transcription factors (23Karns L.R. Kariya K. Simpson P.C. J. Biol. Chem. 1995; 270: 410-417Abstract Full Text Full Text PDF PubMed Scopus (162) Google Scholar, 27Stewart A.F.R. Suzow J. Kubota T. Ueyama T. Chen H.H. Circ. Res. 1998; 83: 43-49Crossref PubMed Scopus (65) Google Scholar, 28Ueyama T. Zhu C. Valenzuela Y.M. Suzow J.G. Stewart A.F.R. J. Biol. Chem. 2000; 275: 17476-17480Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 29Maeda T. Mazzulli J.R. Farrance I.K. Stewart A.F.R. J. Biol. Chem. 2002; 277: 24346-24352Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar). Previously, we observed a 3-fold activation of the skeletal α-actin promoter by α1-adrenergic stimulation (29Maeda T. Mazzulli J.R. Farrance I.K. Stewart A.F.R. J. Biol. Chem. 2002; 277: 24346-24352Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar). Here, we found that the use of collagenase rather than trypsin during myocyte isolation markedly improved the response to phenylephrine, up to 6-fold (Fig. 7; data not shown). The phenylephrine response of the skeletal α-actin promoter in the presence of empty expression vector (pXJ40) reflects the increased activity of endogenous TEF-1 transcription factors (28Ueyama T. Zhu C. Valenzuela Y.M. Suzow J.G. Stewart A.F.R. J. Biol. Chem. 2000; 275: 17476-17480Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 29Maeda T. Mazzulli J.R. Farrance I.K. Stewart A.F.R. J. Biol. Chem. 2002; 277: 24346-24352Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar). Consistent with our previous findings, TEF-1 overexpression inhibited the response to phenylephrine (27Stewart A.F.R. Suzow J. Kubota T. Ueyama T. Chen H.H. Circ. Res. 1998; 83: 43-49Crossref PubMed Scopus (65) Google Scholar), suggesting that exogenous TEF-1 titrates limiting cofactors. Overexpression of Vgl-4 also attenuated the α1-adrenergic activation of the skeletal α-actin promoter (Fig. 7). Vgl-4 may modulate TEF-1 by two possible mechanisms, either by recruiting a co-repressor to TEF-1, as under basal conditions, or by preventing α1-adrenergic modification of TEF-1. The two-hybrid analysis of the effects of Vgl-4 under basal and α1-adrenergic stimulation in cardiac myocytes supports either mechanism. Transcription of a heterologous promoter (pG5-luciferase) was activated by a GAL4 DNA-binding domain/TEF-1 fusion protein under basal conditions and was further activated in response to α1-adrenergic stimulation (Fig. 5). The ability of pMTEF-1 to further activate the pG5-luciferase reporter in response to α1-adrenergic stimulation was abolished in the presence of a chimeric protein containing the activation domain of VP16 fused to Vgl-4 (pVPVgl-4). Thus, Vgl-4 interferes with α1-adrenergic-mediated TEF-1 function. Nuclear localization of Vgl-1 depends on its interaction with TEF-1 because preventing Vgl-4 interaction with TEF-1 by deleting the TDU motifs caused cytoplasmic retention of Vgl-4 (Fig. 8). Interestingly, Vgl-4 moves out of the nucleus of cardiac myocytes treated with the α1-adrenergic agonist phenylephrine (Fig. 6), suggesting that Vgl-4 removal is required to promote the α1-adrenergic response. Forced nuclear retention of Vgl-4 in a chimeric construct carrying a strong nuclear localization signal (Fig. 8) markedly reduced the α1-adrenergic response of the skeletal α-actin promoter (Fig. 7). Conversely, overexpression of a carboxyl-terminal-truncated Vgl-4 lacking the TDU motifs that is retained in the cytoplasm augmented the α1-adrenergic response of the skeletal α-actin promoter (Fig. 7). Overexpression of Vgl-4 likely overwhelms the nuclear export mechanism, and the presence of residual nuclear Vgl-4 could account for the interference of the α1-adrenergic response. Vgl-4 carries a consensus nuclear export signal (see Fig. 1A), a binding site of the nuclear exportin CRM-1 (33Fabbro M. Henderson B.R. Exp. Cell Res. 2003; 282: 59-69Crossref PubMed Scopus (196) Google Scholar). Our studies show that the CRM-1 inhibitor leptomycin B blocks nuclear export of Vgl-4 in phenylephrine-treated cardiac myocytes (Fig. 9). A CRM-1-dependent mechanism controlling nuclear localization of the cardiac transcription factor GATA4 in response to β-adrenergic signaling has been described previously (39Morisco C. Seta K. Hardt S.E. Lee Y. Vatner S.F. Sadoshima J. J. Biol. Chem. 2001; 276: 28586-28597Abstract Full Text Full Text PDF PubMed Scopus (182) Google Scholar). Inactivation of glycogen synthase kinase III prevents CRM-1 interaction with GATA4 and its nuclear export. During development, GATA4 regulates the expression of the cardiac-specific homeobox gene Nkx2.5 that controls cardiac myocyte differentiation (40Brown III, C.O. Chi X. Garcia-Gras E. Shirai M. Feng X.H. Schwartz R.J. J. Biol. Chem. 2004; 279: 10659-10669Abstract Full Text Full Text PDF PubMed Scopus (137) Google Scholar). α1-Adrenergic signaling may unmask the nuclear export domain of Vgl-4 by phosphorylating the 14-3-3 site and thereby allow nuclear export through a CRM-1-dependent mechanism. α1-Adrenergic signaling is known to activate a fetal gene program and to partially reactivate components of the cell cycle in a process of cardiac myocyte dedifferentiation (22Kariya K. Farrance I.K. Simpson P.C. J. Biol. Chem. 1993; 268: 26658-26662Abstract Full Text PDF PubMed Google Scholar, 23Karns L.R. Kariya K. Simpson P.C. J. Biol. Chem. 1995; 270: 410-417Abstract Full Text Full Text PDF PubMed Scopus (162) Google Scholar, 24Vara D. Bicknell K.A. Coxon C.H. Brooks G. J. Biol. Chem. 2003; 278: 21388-21394Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar, 25Busk P.K. Bartkova J. Strom C.C. Wulf-Andersen L. Hinrichsen R. Christoffersen T.E. Latella L. Bartek J. Haunso S. Sheikh S.P. Cardiovasc. Res. 2002; 56: 64-75Crossref PubMed Scopus (64) Google Scholar). In this respect, it is important to note that the Drosophila Vestigial protein is required for cell proliferation in the wing primordium (41Martín-Castellanos C. Edgar B.A. Development (Camb.). 2002; 129: 1003-1013PubMed Google Scholar, 42Paumard-Rigal S. Zider A. Vaudin P. Silber J. Dev. Genes Evol. 1998; 208: 440-446Crossref PubMed Scopus (74) Google Scholar), suggesting that members of the Vestigial family of transcription cofactors may participate in regulating the transition from proliferation to cell cycle arrest and differentiation. Thus, like GATA4, regulating the nuclear localization of Vgl-4 may play a role in cardiac myocyte differentiation. Although we do not yet know the genes that are regulated by Vgl-4 through their interaction with TEF-1 factors, one likely outcome of this interaction is a change in DNA binding specificity at muscle-specific promoters. In Drosophila, Vestigial interaction with Scalloped alters DNA binding specificity and activates many wing-specific genes (14Halder G. Carroll S.B. Development (Camb.). 2001; 128: 3295-3305PubMed Google Scholar) and allows the differentiation of indirect flight muscles (11Sudarsan V. Anant S. Guptan P. VijayRaghavan K. Skaer H. Dev. Cell. 2001; 1: 829-839Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar). Whether Vgl-4 also affects TEF-1 target selectivity remains to be determined. We are grateful to Prof. Joseph Yip for the use of his fluorescence microscope and digital imaging system." @default.
• W2003234142 created "2016-06-24" @default.
• W2003234142 creator A5001575849 @default.
• W2003234142 creator A5025846764 @default.
• W2003234142 creator A5071151211 @default.
• W2003234142 date "2004-07-01" @default.
• W2003234142 modified "2023-09-30" @default.
• W2003234142 title "Vgl-4, a Novel Member of the Vestigial-like Family of Transcription Cofactors, Regulates α1-Adrenergic Activation of Gene Expression in Cardiac Myocytes" @default.
• W2003234142 cites W1509665044 @default.
• W2003234142 cites W1532539575 @default.
• W2003234142 cites W1562563314 @default.
• W2003234142 cites W1824332008 @default.
• W2003234142 cites W1838990806 @default.
• W2003234142 cites W1967622017 @default.
• W2003234142 cites W1972271676 @default.
• W2003234142 cites W1980156049 @default.
• W2003234142 cites W1983207595 @default.
• W2003234142 cites W1994970453 @default.
• W2003234142 cites W2004537703 @default.
• W2003234142 cites W2010287515 @default.
• W2003234142 cites W2015615030 @default.
• W2003234142 cites W2016568814 @default.
• W2003234142 cites W2020208784 @default.
• W2003234142 cites W2022083392 @default.
• W2003234142 cites W2028036560 @default.
• W2003234142 cites W2029813220 @default.
• W2003234142 cites W2031795488 @default.
• W2003234142 cites W2050208964 @default.
• W2003234142 cites W2052137719 @default.
• W2003234142 cites W2052763120 @default.
• W2003234142 cites W2056311227 @default.
• W2003234142 cites W2063812215 @default.
• W2003234142 cites W2068216249 @default.
• W2003234142 cites W2071075259 @default.
• W2003234142 cites W2073681698 @default.
• W2003234142 cites W2082209421 @default.
• W2003234142 cites W2093508001 @default.
• W2003234142 cites W2107651170 @default.
• W2003234142 cites W2110889457 @default.
• W2003234142 cites W2119015041 @default.
• W2003234142 cites W2119932025 @default.
• W2003234142 cites W2135801344 @default.
• W2003234142 cites W2150192232 @default.
• W2003234142 cites W2155365737 @default.
• W2003234142 cites W2155583879 @default.
• W2003234142 cites W2159196011 @default.
• W2003234142 cites W2162227691 @default.
• W2003234142 cites W2189265592 @default.
• W2003234142 cites W4247868313 @default.
• W2003234142 doi "https://doi.org/10.1074/jbc.m400154200" @default.
• W2003234142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15140898" @default.
• W2003234142 hasPublicationYear "2004" @default.
• W2003234142 type Work @default.
• W2003234142 sameAs 2003234142 @default.
• W2003234142 citedByCount "98" @default.
• W2003234142 countsByYear W20032341422012 @default.
• W2003234142 countsByYear W20032341422013 @default.
• W2003234142 countsByYear W20032341422014 @default.
• W2003234142 countsByYear W20032341422015 @default.
• W2003234142 countsByYear W20032341422016 @default.
• W2003234142 countsByYear W20032341422017 @default.
• W2003234142 countsByYear W20032341422018 @default.
• W2003234142 countsByYear W20032341422019 @default.
• W2003234142 countsByYear W20032341422020 @default.
• W2003234142 countsByYear W20032341422021 @default.
• W2003234142 countsByYear W20032341422022 @default.
• W2003234142 countsByYear W20032341422023 @default.
• W2003234142 crossrefType "journal-article" @default.
• W2003234142 hasAuthorship W2003234142A5001575849 @default.
• W2003234142 hasAuthorship W2003234142A5025846764 @default.
• W2003234142 hasAuthorship W2003234142A5071151211 @default.
• W2003234142 hasBestOaLocation W20032341421 @default.
• W2003234142 hasConcept C104317684 @default.
• W2003234142 hasConcept C138885662 @default.
• W2003234142 hasConcept C150194340 @default.
• W2003234142 hasConcept C153911025 @default.
• W2003234142 hasConcept C179926584 @default.
• W2003234142 hasConcept C181199279 @default.
• W2003234142 hasConcept C185592680 @default.
• W2003234142 hasConcept C197957613 @default.
• W2003234142 hasConcept C207200792 @default.
• W2003234142 hasConcept C41895202 @default.
• W2003234142 hasConcept C54355233 @default.
• W2003234142 hasConcept C55493867 @default.
• W2003234142 hasConcept C86339819 @default.
• W2003234142 hasConcept C86803240 @default.
• W2003234142 hasConcept C95444343 @default.
• W2003234142 hasConceptScore W2003234142C104317684 @default.
• W2003234142 hasConceptScore W2003234142C138885662 @default.
• W2003234142 hasConceptScore W2003234142C150194340 @default.
• W2003234142 hasConceptScore W2003234142C153911025 @default.
• W2003234142 hasConceptScore W2003234142C179926584 @default.
• W2003234142 hasConceptScore W2003234142C181199279 @default.
• W2003234142 hasConceptScore W2003234142C185592680 @default.
• W2003234142 hasConceptScore W2003234142C197957613 @default.
• W2003234142 hasConceptScore W2003234142C207200792 @default.
• W2003234142 hasConceptScore W2003234142C41895202 @default.
• W2003234142 hasConceptScore W2003234142C54355233 @default.

• next